Investigational drug · Phase 2
Pepinemab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Pancreatic Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: May 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "Pepinemab"
First trial start
2022
Dec 10, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pepinemab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Pancreatic Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Pepinemab" as an intervention, largest first.
- A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of PepiPivotal-lookingCompleted
Vaccinex Inc.Industry
NCT02481674 · 301 participants · Start Jul 2015 · Primary completion Aug 2020
Drug: VX15/2503; Placebo · For: Huntington's Disease
Sites: Birmingham, Alabama; La Jolla, California; San Francisco, California · 32 sites in all
Vaccinex Inc.Industry
NCT04381468 · 50 participants · Start Jul 22, 2021 · Primary completion Jun 5, 2024
Drug: Pepinemab; Placebo · For: Alzheimer Disease
Sites: San Diego, California; Washington D.C., District of Columbia; Delray Beach, Florida · 14 sites in all
Vaccinex Inc.Industry
NCT04815720 · 49 participants · Start Aug 9, 2021 · Primary completion Jul 24, 2024
Drug: pepinemab + pembrolizumab · For: Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Sites: Springdale, Arkansas; Fresno, California; San Francisco, California · 15 sites in all
- Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaActive, not recruiting
Vaccinex Inc.Industry
NCT05102721 · 48 participants (planned) · Start Dec 10, 2022 · Primary completion Dec 31, 2028
Drug: Avelumab and Pepinemab · For: Metastatic Pancreatic Adenocarcinoma
Sites: Rochester, New York
- VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaActive, not recruiting
Emory UniversityAcademic, hospital or other
NCT03769155 · 41 participants · Start Dec 13, 2018 · Primary completion Dec 15, 2023
Drug: Ipilimumab; Nivolumab and 1 more · For: Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Sites: Atlanta, Georgia
- VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerActive, not recruiting
Emory UniversityAcademic, hospital or other
NCT03690986 · 35 participants · Start Nov 1, 2018 · Primary completion Apr 9, 2027
Drug: VX15/2503; Ipilimumab and 1 more · For: Squamous Cell Carcinoma of the Head and Neck
Sites: Atlanta, Georgia
H. Lee Moffitt Cancer Center and Research InstituteAcademic, hospital or other
NCT05378464 · 28 participants (planned) · Start May 31, 2022 · Primary completion Aug 17, 2026
Drug: Dendritic Cell (DC1) Vaccine; Trastuzumab and 2 more · For: HER2-positive Breast Cancer
Sites: Tampa, Florida
- Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid TumorsCompleted
Children's Oncology GroupResearch network
NCT03320330 · 26 participants · Start Jan 31, 2018 · Primary completion Dec 31, 2020
Drug: Pepinemab · For: Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Refractory Malignant Solid Neoplasm and 1 more
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 24 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial.
Ruffin AT, Mallow CL, Olson BM, et al. · Nat Commun 2026
- Context-Dependent Dual Roles of the Plexin-B Family in Cancer Progression: Mechanisms and Therapeutic Implications.
Mao X, Lin W, Zhang X, et al. · Cancer Manag Res 2026
- Regulation of Vascular Calcification by M1-Type Macrophage-Derived Semaphorin 4D.
Park HJ, Kim Y, Kim MK, et al. · Int J Mol Sci 2025
- Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases.
Feigin A, Evans EE, Fisher TL, et al. · Expert Opin Investig Drugs 2025
- A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614).
Greengard E, Williams R, Moriarity B, et al. · Pediatr Blood Cancer 2024
- Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, et al. · Nat Med 2024
Also in development for Metastatic Pancreatic Adenocarcinoma
- SetidegrasibASP3082Phase 32 trials
Astellas · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- IvaltinostatPhase 21 trial
CG Pharmaceuticals, Inc · Metastatic Pancreatic Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.